Non-Oncology Case Study of Lonafarnib

Hutchinson-Gilford progeria syndrome is a rare and fatal premature aging disorder caused by gene mutations resulting in the accumulation of abnormal proteins like progerin. Lonafarnib, a farnesyltransferase inhibitor, emerged as a potential treatment for HGPS. This chapter outlines lonafarnib’s development program, supported by pivotal trials comparing treated patients to a natural history cohort. Utilizing the Progeria Research Foundation International Progeria Registry database, rigorous matching criteria were applied to minimize bias in the analysis. Statistical methods, including log-rank tests and Cox proportional hazards regression, were applied to demonstrate lonafarnib’s efficacy in prolonging survival. The chapter concludes with remarks on lonafarnib’s approval by the FDA and reflections on the use of external controls in successful drug development, suggesting avenues for refining trial designs to further enhance efficacy evaluations.